Chinese Biotech Bets On Intravenous 3CL Antiviral Contender For COVID-19

 
• By Dexter Jie Yan

While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.

Frontier CEO on antiviral drugs
small Chinese biotech moving forward with IV antiviral for COVID-19 • Source: Alamy

More from China

More from Focus On Asia